ChemicalBook CAS DataBase List Emibetuzumab

Emibetuzumab

Product NameEmibetuzumab
CAS1365287-97-3
CBNumberCB28080907
MW0
MOL FileMol file
MSDS FileSDS

Chemical Properties

form	Liquid
color	Colorless to light yellow
FDA UNII	MO4K3GDN1I

Emibetuzumab Price

Product number	Packaging	Price	Product description	Buy
ChemScene CS-0612940	1mg	$195	Emibetuzumab 95.00%	Buy
ChemScene CS-0612940	5mg	$585	Emibetuzumab 95.00%	Buy
ChemScene CS-0612940	10mg	$932	Emibetuzumab 95.00%	Buy
aablocks AA02A8IR	1mg	$138	Emibetuzumab	Buy
aablocks AA02A8IR	5mg	$378	Emibetuzumab	Buy

Emibetuzumab Chemical Properties,Usage,Production

Description

Emibetuzumab is a bivalent antibody that blocks HGF- and MET-receptor interaction, leading to MET internalization and degradation.

Uses

Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer[1].

Clinical Use

A phase I study determined a tolerable dose for emibetuzumab to be 700–2000 mg as a monotherapy and in combination with erlotinib in NSCLC patients. It is currently being investigated in phase II in combination with erlotinib.

in vivo

Emibetuzumab (LY2875358) (10 mg/kg; i.v.; once a week for 5 weeks) inhibits in vivo growth of glioblastoma U87MG xenograft tumors in mice^[1].
Emibetuzumab (10 or 20 mg/kg; i.v.; single) downregulates levels of MET and pMET in the tumors of mice^[1].
Emibetuzumab (10 mg/kg; i.v.; once a week for 3, 5 or 6 weeks) exhibits antitumor effects on MET-amplified xenograft mouse tumor models^[1].

Animal Model:	Athymic nude mice (U87MG tumor xenograft model)^[1].
Dosage:	10 mg/kg
Administration:	Intravenous injection, once a week for 5 weeks.
Result:	Demonstrated a significant inhibition of tumor growth.

Animal Model:	Athymic nude mice (MKN45 xenograft tumor model)^[1].
Dosage:	10 or 20 mg/kg
Administration:	Intravenous injection, single.
Result:	Reduced MET and pMET in the tumors by approximately 50% at both the 10 and 20 mg/kg doses by 72 hours post dose, and the reductions persisted to 14 days.

Animal Model:	Athymic nude mice (MET-amplified xenograft mouse tumor models)^[1].
Dosage:	10 mg/kg
Administration:	Intravenous injection, once a week for 3, 5 or 6 weeks.
Result:	Resulted in a marked reduction in tumor growth in the MKN45/SNU-5/EBC-1 gastric xenograft tumors.

References

[1] Liu L, et al. LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth. Clin Cancer Res. 2014 Dec 1;20(23):6059-70. DOI:10.1158/1078-0432.CCR-14-0543

Preparation Products And Raw materials

Emibetuzumab Suppliers

Supplier	Tel	Email	Country	ProdList	Advantage
Shanghai YuanYe Biotechnology Co., Ltd.	15026964105	2881489226@qq.com	China	87240	60
ShangHai Biochempartner Co.,Ltd	177-54423994 17754423994	2853530910@QQ.com	China	7996	62
BOC Sciences	16314854226; +8616314854226	inquiry@bocsci.com	United States	19852	58
Guangzhou Hongyuan Chemical Co.,Ltd	15817493340	981810490@qq.com	China	1577	58
Wuhan Chemstan Biotechnology Co., Ltd.	027-65317797 15926423062	422450190@qq.com	China	10302	58
Beijing Jin Ming Biotechnology Co., Ltd.	010-60605840	psaitong@jm-bio.com	China	27626	58
TargetMol Chemicals Inc.	4008200310 15002144251	marketing@tsbiochem.com	China	24951	58
Biolab Reagents	027-65279366 18108604356	products@biolabreagent.com	China	9864	58
Wuhan Jingkangen Biomedical Technology Co., Ltd	13720134139 086-15871494362 13720134139	orders@jknbiochem.com	China	7283	58
Shanghai Yifei Biotechnology Co. , Ltd.	021-65675885 18964387627	customer_service@efebio.com	China	11963	58

1365287-97-3, EmibetuzumabRelated Search

Send Inquiry